DEA proposes increased psychedelic production for research

The U.S. Drug Enforcement Administration (DEA) is planning a substantial increase in the legal production of certain psychedelics, including ibogaine and MDMA, by 2027. This initiative aims to support the growing number of medical and scientific research projects exploring these substances as potential treatments for conditions like post-traumatic stress disorder (PTSD) and depression, according to a draft notice in the Federal Register.

Increased Production Plans

The DEA's proposal outlines a significant rise in the production quotas for MDMA and ibogaine. In 2026, the agency permitted the production of 12,000 grams of MDMA. This figure is set to nearly triple to 33,296 grams by 2027. Similarly, ibogaine production is expected to jump from 210 grams to 12,002 grams in the same period. The increase is intended to accommodate the "increased level of research and clinical trials" involving these substances.

Regulatory Context

The proposed production increase aligns with two executive orders aimed at enhancing addiction treatment and expanding the use of psychedelic drugs for mental health treatment under the Right to Try Act. This act, signed by former President Donald Trump in April, allows terminally ill patients to access experimental therapies that have not yet received full FDA approval. At the time, Trump highlighted the "life-changing potential" of drugs like psilocybin, ibogaine, LSD, and MDMA.

Why It Matters

The DEA's decision to boost production quotas for psychedelics like ibogaine and MDMA reflects a growing recognition of their potential therapeutic benefits. As research into these substances expands, increased availability could facilitate more comprehensive studies, potentially leading to new treatments for mental health disorders. The University of Miami's recent donation of its original 1994 ibogaine IND application to the federal government further underscores the momentum behind psychedelic research.

The DEA's proposal signals a shift towards embracing the potential of psychedelics in medical research, which could pave the way for new therapeutic options.